![conference banner](/images/conference-banner.jpeg)
Abstract
The thrombopoiesis-stimulating agents (TSAs) are a novel class of drugs for the treatment of chronic immune thrombocytopenia (ITP). Roimplostim and eltrombopag, the first two TSAs to enter clinical use, received regulatory approval in 2008 and stand poised to change the treatment paradigm in ITP. However, important questions regarding the safety of these agents, particularly with long-term use, remain partially unanswered. The primary objective of this article is to review the reported toxicities associated with the TSAs including rebound thrombocytopenia, thrombosis, hepatotoxicity, formation of neutralizing antibodies, bone marrow fibrosis, hematologic malignancy, cataract formation, and common adverse events. The incidence and severity of these toxicities as well as strategies for monitoring patient safety and pharmacovigilance are discussed.
Keywords: ITP, thrombopoiesis, romiplostim, eltrombopag
Current Drug Safety
Title: Safety of the Thrombopoiesis-Stimulating Agents for the Treatment of Immune Thrombocytopenia
Volume: 5 Issue: 2
Author(s): Adam Cuker, Elaine Y. Chiang and Douglas B. Cines
Affiliation:
Keywords: ITP, thrombopoiesis, romiplostim, eltrombopag
Abstract: The thrombopoiesis-stimulating agents (TSAs) are a novel class of drugs for the treatment of chronic immune thrombocytopenia (ITP). Roimplostim and eltrombopag, the first two TSAs to enter clinical use, received regulatory approval in 2008 and stand poised to change the treatment paradigm in ITP. However, important questions regarding the safety of these agents, particularly with long-term use, remain partially unanswered. The primary objective of this article is to review the reported toxicities associated with the TSAs including rebound thrombocytopenia, thrombosis, hepatotoxicity, formation of neutralizing antibodies, bone marrow fibrosis, hematologic malignancy, cataract formation, and common adverse events. The incidence and severity of these toxicities as well as strategies for monitoring patient safety and pharmacovigilance are discussed.
Export Options
About this article
Cite this article as:
Cuker Adam, Chiang Y. Elaine and Cines B. Douglas, Safety of the Thrombopoiesis-Stimulating Agents for the Treatment of Immune Thrombocytopenia, Current Drug Safety 2010; 5 (2) . https://dx.doi.org/10.2174/157488610790936196
DOI https://dx.doi.org/10.2174/157488610790936196 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Triterpenoids for Cancer Prevention and Treatment: Current Status and Future Prospects
Current Pharmaceutical Biotechnology Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS
Current Pharmaceutical Design A Novel Technology for Hematopoietic Stem Cell Expansion Using Combination of Nanofiber and Growth Factors
Recent Patents on Nanotechnology Dose-Intensive Chemotherapy with Stem Cell Support as a Treatment Strategy for Bone and Soft-Tissue Sarcomas
Current Stem Cell Research & Therapy Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
Current Pharmaceutical Design Target-oriented Mechanisms of Novel Herbal Therapeutics in the Chemotherapy of Gastrointestinal Cancer and Inflammation
Current Pharmaceutical Design MicroRNAs and Cancer; an Overview
Current Pharmaceutical Biotechnology Prospects and Limitations of T Cell Receptor Gene Therapy
Current Gene Therapy Silencing MFHAS1 Induces Pyroptosis <i>via</i> the JNK-activated NF-κB/Caspase1/ GSDMD Signal Axis in Breast Cancer
Current Pharmaceutical Design Caenorhabditis elegans: A Model for Studying Human Pathogen Biology
Recent Patents on Biotechnology Sphingolipid Signaling and Hematopoietic Malignancies: To the Rheostat and Beyond
Anti-Cancer Agents in Medicinal Chemistry Omacetaxine as an Anticancer Therapeutic: What is Old is New Again
Current Pharmaceutical Design ARC - Augmented Renal Clearance
Current Pharmaceutical Biotechnology Cationic Liposomes as Non-viral Vector for RNA Delivery in Cancer Immunotherapy
Recent Patents on Drug Delivery & Formulation Drug Resistance in Childhood Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Erythropoiesis Stimulating Agents and Techniques: A Challenge for Doping Analysts
Current Medicinal Chemistry Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery RO3280: A Novel PLK1 Inhibitor, Suppressed the Proliferation of MCF-7 Breast Cancer Cells Through the Induction of Cell Cycle Arrest at G2/M Point
Anti-Cancer Agents in Medicinal Chemistry Role of Polymorphisms in Factor V (FV Leiden), Prothrombin, Plasminogen Activator Inhibitor Type-1 (PAI-1), Methylenetetrahydrofolate Reductase (MTHFR) and Cystathionine β-Synthase (CBS) Genes as Risk Factors for Thrombophilias
Mini-Reviews in Medicinal Chemistry Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) δ and γ
Current Topics in Medicinal Chemistry